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Background: Nucleoside analogs labeled with positrons, such as 11C and 18F, are considered valuable in visualizing
the proliferative activity of tumor cells in vivo using positron emission tomography (PET). We recently developed
the 11C-labeled thymidine analogs [11C]zidovudine ([11C]AZT) and [11C]stavudine ([11C]d4T) via the Pd(0)-Cu(I)
co-mediated rapid C–C coupling reaction. In this study, to examine whether [11C]AZT and [11C]d4T might be useful
for visualization of tumors in vivo, we performed PET imaging, tissue distribution studies, and metabolite analysis in
tumor-bearing mice.
Methods: Mice bearing tumors (rat glioma C6 and human cervical adenocarcinoma HeLa cells) were injected with
50 MBq of [11C]AZT or [11C]d4T, and PET was performed immediately thereafter. After PET imaging, the radioactivity
in several tissues, including tumor tissues, was measured using a γ-counter. In addition, radioactive metabolites in
plasma, bile, intestinal contents, and tumor were analyzed using thin layer chromatography (TLC). Cellular uptake of
[11C]AZT in C6 was measured in the presence or absence of non-labeled thymidine (0.1 mM).
Results: In PET studies, C6 and HeLa tumors in mice were clearly visualized using [11C]AZT. Time-activity curves
using [11C]AZT showed that the accumulation of radioactivity in tumors plateaued at 10 min after injection and
persisted for 60 min, while most of the radioactivity in other tissues was rapidly excreted into the urine. In various
tissues of the body, tumor tissue showed the highest radioactivity at 80 min after injection (five to six times higher
uptake than that of blood). Compared with tumor tissue, uptake was lower in other proliferative tissues such as the
spleen, intestine, and bone marrow, resulting in a high tumor-to-bone marrow ratio. Cellular uptake of [11C]AZT in
C6 cells was completely blocked by the application of thymidine, strongly indicating the specific involvement of
nucleoside transporters. In contrast, the time-activity curve of [11C]d4T in the tumor showed transient and rapid
excretion with almost no obvious tumor tissue accumulation.
Conclusions: Tumors can be detected by PET using [11C]AZT; therefore, [11C]AZT could be useful as a novel PET
tracer for tumor imaging in vivo.
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Thymidine analog nucleoside reverse transcriptase inhibi-
tors (NRTIs) such as zidovudine (AZT) and stavudine
(d4T) suppress the replication of human immunodefi-
ciency virus (HIV) and are now used in the treatment of
acquired immunodeficiency syndrome (AIDS) [1, 2]. Al-
though AZT was the first anti-HIV drug to be approved
worldwide, it was originally designed as an antitumor
agent due to its prevention of DNA elongation by inhibit-
ing the incorporation of thymidine into the DNA of can-
cer cells [3, 4].
Increased cell proliferative activity is a prominent fea-
ture of tumor cells. The capacity to non-invasively meas-
ure this proliferative activity is a potent tool in the
clinical detection and diagnosis of tumors. In order to
measure tumor proliferative activity using positron emis-
sion tomography (PET), several thymidine analogs have
been labeled with positron-emitting nuclei, such as 11C
and 18F [5–11]. One of the most promising PET tracers
for proliferation imaging is 4′-[methyl-11C]thiothymi-
dine ([11C]4DST), which is resistant to degradation by
thymidine phosphorylase, and can be incorporated into
DNA [5]. Although [11C]4DST has shown high accumula-
tion in tumors in mouse models and in patients [5, 12,
13], concomitant accumulation occurred in normal tis-
sues, such as the bone marrow, spleen, thymus, and intes-
tine, because of their relatively high proliferative activity.Fig. 1 Scheme showing the synthesis of [11C]zidovudine (AZT), [11C]stavudWe recently succeeded in the 11C-labeling of two anti-
HIV drugs, to produce [11C]AZT and [11C]d4T, via the
Pd(0)-Cu(I) co-mediated rapid C-C coupling reaction
(Fig. 1) [14]. These labeled drugs may have potential
roles as PET probes, not only in tumor diagnosis, but
also in the evaluation of AIDS/HIV infection. In the
present study, to evaluate whether these novel 11C-la-
beled probes might be useful in PET tumor imaging, we
performed the following studies: (1) tissue distribution
of the probes on PET imaging of C6 and HeLa tumor-
bearing mice; (2) metabolite analysis by thin-layer chro-
matography (TLC) of plasma, bile, and tumor samples;




Silica-gel RP-18 F254s TLC plates were purchased from
Merck (Darmstadt, Germany) and 1.0-ml syringes were
purchased from Terumo (Tokyo, Japan). Two AZT me-
tabolites, 3′-Azido-3′-deoxythymidine 5′-monophosphate
sodium salt and 3′-Azido-3′-deoxythymidine β-D-glucu-
ronide sodium salt were purchased from Carbosynth Lim-
ited (Berkshire, UK) and Toronto Research Chemicals
(Toronto, Canada), respectively. All other chemicals were
purchased from Wako (Tokyo, Japan) or Nacalai Tesque
(Kyoto, Japan) and were of analytical grade.ine (d4T), and 4′-[methyl-11C]thiothymidine ([11C]4DST) [14]
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[11C]Carbon dioxide was produced by a 14N(p,α)11C re-
action using a CYPRIS HM-12S cyclotron (Sumitomo
Heavy Industries, Tokyo, Japan), and was then converted
into [11C]CH3I by LiAlH4 reduction followed by HI treat-
ment, using an original automated synthesis system for
11C-labeling in RIKEN CLST. The obtained [11C]CH3I
was used for the Pd(0)-Cu(I) co-mediated rapid
[11C]methylation with precursors 3′-azido-2′,3′-dideoxy-
5-(tributylstannyl)-uridine, 2′,3′-didehydro-2′,3′-dideoxy-
5-(tributylstannyl)-uridine and 5-tributylstannyl-4′-thio-
2′-deoxyuridine to generate the PET tracers [11C]AZT,
[11C]d4T and [11C]4DST, respectively (Fig. 1) [14].
Animal models
All experimental protocols were approved by the Animal
Care and Use Committee of RIKEN Kobe Institute
(MAH24-03) and were performed according to the
guidelines for animal experiments published by the Na-
tional Institutes of Health [15]. Rat glioma C6 and hu-
man cervix adenocarcinoma HeLa cells were grown in
Dulbecco’s modified Eagle’s medium supplemented with
10 % fetal bovine serum and 100 μg/ml of penicillin-
streptomycin. Five-week-old female BALB/c-nu/nu mice
were obtained from CLEA Japan (Tokyo, Japan) and
were held for 1 week prior to the experiment. Tumor-
bearing mice were established by subcutaneous injection
of tumor cells into the shoulder of mice (1 × 106 cells for
C6 and 5 × 106 cells for HeLa), as described previously
[16]. The mice were used for imaging experiments when
the tumors had grown to approximately 5 to 10 mm in
diameter.
For examination of tracer accumulation in the inflam-
matory area, mice were injected 0.03 ml of turpentine
oil into the right thigh and were conducted to the PET
imaging 3 days after the administration [17].
MicroPET imaging
A small animal PET scanner (microPET Focus220, Sie-
mens Medical Systems, Erlangen, Germany) was used
for the imaging studies of the mice. A venous indwelling
catheter was inserted into the tail vein for probe injec-
tion before PET scanning. Animals were kept on a heat-
ing pad to maintain a body temperature of 37 °C. The
probes ([11C]AZT, [11C]d4T and [11C]4DST at a concen-
tration of 50 MBq/0.1 ml) were injected under 1.5 % iso-
flurane anesthesia, and dynamic PET scans (6 × 10 s, 6 ×
30 s, 11 × 60 s, and 15 × 180 s) were performed for
60 min, immediately after probe injection. For inflamma-
tion imaging with [18F]FDG (5 MBq/0.1 ml), mice fasted
for 4 h before injection were kept for 50 min in awake
state and then were anesthetized with 1.5 % isoflurane to
image during 60–80 min after the injection. Emission
data were acquired using a 3D list-mode method, andPET images were reconstructed using the filtered back
projection algorithm. The maximum-intensity-projection
images were displayed using ASIPro software (Concorde
Microsystems, Knoxville, USA). The uptake of the
probes in tissues is shown as standardized uptake value
(SUV).
Tissue distribution
A concentration of 50 MBq of probes in 100 μl of saline
was injected into tumor-bearing mice via the tail vein.
The mice were sacrificed under deep anesthesia with
3.0 % isoflurane at 80 min after the injection, and the
blood, urine, brain, heart, lungs, liver, kidneys, spleen,
pancreas, quadriceps muscles, ovaries, duodenum, intes-
tinal contents, bone, and tumors were then collected,
and their volumes and weights were promptly measured.
The radioactivity in the various tissues, whole blood
(WB), plasma, and urine samples was measured using a
γ-well counter (Wizard 1480; PerkinElmer, Waltham,
USA). The results are expressed as %ID/g [18].
Thin layer chromatography
Metabolite analysis using thin layer chromatography
(TLC) was performed for plasma, bile, intestinal con-
tents, and tumor samples that were obtained at 30 or
60 min after probe injection. The blood sample was col-
lected by cardiac puncture using a heparinized syringe
under deep anesthesia with 3.0 % isoflurane. Subse-
quently, the blood was centrifuged at 16,000×g at 4 °C
for 2 min, and the plasma (approximately 100 μl) was
vortexed with an equal volume of acetonitrile. After cen-
trifugation at 16,000×g at 4 °C for 2 min, the supernatant
was collected as the TLC sample. To prepare TLC sam-
ples from the liver and tumor, weighed tissues were
added to an equal volume (w/v) of distilled water, and
were homogenized and centrifuged. The supernatants
were vortexed with three volumes (v/v) of acetonitrile
and were then centrifuged. The supernatants were col-
lected and used as TLC samples. Aliquots of the
acetonitrile-treated supernatants (2.0 μl) were then spot-
ted on a TLC plate Silica-gel 60 RP-18 and were devel-
oped with the solvent (CH3CN/phosphate buffer (pH
6.8) = 15:85) until the front line reached 7 cm from the
origin. The TLC plate was then placed on an imaging
plate (BAS-SR2040; Fuji Photo Film Co., Tokyo, Japan)
for 1 h, and the exposed imaging plate was scanned with
a fluoro-image analyzer (FLA-7000IR; Fuji Photo Film).
The proportion of each [11C]AZT metabolite was calcu-
lated based on the radioactivity in each metabolite
(photostimulable luminescence/mm2).
[11C]AZT cell uptake study with thymidine
For the uptake study, C6 cells were seeded on 6-well
plates at a density of 2 × 105 cells/well for 24 h. Cellular
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1.4 MBq/well) in the presence or absence of non-labeled
thymidine (0.1 mM), and the cells were incubated at
37 °C for 30 min. Uptake was terminated by adding ice-
cold phosphate-buffered saline, and the cells were
washed three times with this buffer. The cells were
lysed with buffer (25 mM Tris-HCl, pH 7.4, 2.5 mM
EDTA, 1 % Triton X-100), and the radioactivity of the
lysate was measured using a γ-well counter. Cellular
protein concentrations were determined by the Coo-
massie blue method [19] using bovine serum albumin
as the standard. All experiments were performed in
triplicate.
Statistical analysis
Data are expressed as means ± SD groups were com-
pared using one-way or repeated measure (RM) two-way
analysis of variance (ANOVA), and the Bonferroni
method was used for the post hoc multiple comparison
procedure with a significant level of p < 0.05.
Results
PET imaging with [11C]AZT
The whole-body summed PET images obtained between
60 and 80 min after injection of [11C]AZT clearly dem-
onstrated high uptake in C6 tumors (Fig. 2a). This probe
was detected not only in the mice bearing C6 tumors,
but also in those bearing HeLa tumors (Additional file 1:
Figure S1). In contrast, there was lower uptake of
[11C]d4T in both C6 and HeLa tumors (Fig. 2b and Add-
itional file 1: Figure S1, respectively). Time-activity
curves (TACs) demonstrated that the radioactivity of
[11C]AZT in both tumors plateaued at 10 min and was
maintained at this level until 60 min after injectionFig. 2 PET imaging of C6 tumor-bearing mice after injection of [11C]AZT or
tumor-bearing mice (n = 4) after injection of 50 MBq / 0.1 ml of [11C]AZT ((Fig. 3a). There was no remarkable accumulation of
[11C]AZT in normal tissues (e.g., heart, liver, spleen, and
kidney) in both C6- and HeLa-bearing mice (Fig. 3b),
but it did gradually accumulate in the urine over time
on PET (data not shown). Additionally, we performed
the PET studies with turpentine oil-induced inflamma-
tion model mice. [11C]AZT did not accumulate in in-
flammatory area (Additional file 1: Figure S2A-F).
Tissue distribution of [11C]AZT in tumor-bearing mice
To investigate the tissue distribution of [11C]AZT in de-
tail, we sacrificed the tumor-bearing mice at 80 min after
injection and measured the radioactivity in the blood,
urine, and several tissues including tumor tissues. Of the
tissues tested, radioactivity levels were highest in the tu-
mors (five to six times higher uptake than in blood), and
radioactivity levels in the tumors were also higher than
in other proliferative tissues such as the spleen, intestine,
and bone marrow (Fig. 4). Since the TAC of [11C]d4T in
the tumors showed transient and rapid excretion, with
no observed accumulation as shown in Fig. 3a, the tissue
distribution of [11C]d4T was not analyzed in further
detail.
Comparison of the accumulation of thymidine analogs in
normal proliferative tissues of a C6 glioma-bearing mouse
by PET analysis
To compare the differences in the pattern of accumula-
tion of three 11C-labeled thymidine analogs in normal
proliferative tissues in vivo, we performed PET analysis
of injected C6 tumor-bearing mice under the same con-
ditions and analyzed the ratio of tumor accumulation to
bone accumulation for each analog in PET images. As
shown in Fig. 5a, b and Additional file 1: Figure S3A,[11C]d4T. Projection PET images (60 to 80 min) of representative C6
a) or [11C]d4T (b) are shown. Arrows indicate the C6 tumors
Fig. 3 Time activity curves of injected [11C]AZT or [11C]d4T in the
tissues of tumor-bearing mice. (a) Time changes of activity of
[11C]AZT (expressed as Closed) or [11C]d4T (expressed as Opened) in
C6 (expressed as Diamond) and HeLa (expressed as Square) tumor
tissues over 3600 s. Statistical analysis of [11C]AZT injected mice vs
[11C]d4T injected mice by RM two-way ANOVA indicates a significant
difference, ***P < 0.001. (b) The uptake of [11C]AZT by tumor and
several normal tissues over 3600 s after injection into C6 or HeLa
tumor-bearing mice (n = 3 per group). The data were averaged
















Fig. 4 Tissue distribution of [11C]AZT in the tumor-bearing mice at
80 min after injection. The radioactivity in the indicated tissues,
whole blood (WB), plasma, and urine samples of C6 (n = 4) and
HeLa (n = 5) bearing mice was measured using a g-well counter at
80 min after injection of [11C]AZT. The results are presented as
means ± S.D. of %ID / g. One way ANOVA; No significant
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tion (3.5 times higher than the tumor accumulation of
[11C]AZT), it was also highly accumulated in the bone.
Thus, of the two thymidine analogs examined, [11C]4DST
and [11C]AZT showed the lowest and highest tumor-to-
bone ratios, respectively (Fig. 5c and Additional file 1:
Figure S3B, p < 0.05).
Metabolite analysis of [11C]AZT
Metabolite analysis of plasma, bile, intestinal contents,
and tumor at 30 or 60 min after the injection of[11C]AZT was then performed using TLC (Fig. 6a).
Three major hydrophilic metabolites were detected: me-
tabolites a, b, and c. To identify these metabolites, we
carried out TLC with major AZT metabolites, AZT-5′-
monophosphate (AZT-P) and AZT-β-D-glucuronide
(AZT-G) (Fig. 6b). In plasma, the unmetabolized form of
[11C]AZT constituted 93.3 ± 2.4 % of the total radioactiv-
ity; in the tumors, it accounted for approximately 50 %
of the total radioactivity, with large amounts of metabol-
ite a (45.6 ± 3.1 %) being present. The other metabolites,
metabolite b and c were observed in the bile. The per-
centages of metabolites b and c in the bile were 9.2 ±
2.3 % and 39.6 ± 5.5 %, respectively. The Rf values of me-
tabolite a and b were consistent with that of AZT-P and
AZT-G, respectively (Fig. 6a, b).
In vitro [11C]AZT uptake study using tumor cells
To investigate whether nucleotide transporters are in-
volved in [11C]AZT uptake in C6 tumors, we performed
an uptake study using thymidine as a competitor. As
shown in Fig. 7, the uptake of [11C]AZT into C6 cells
was completely inhibited by the addition of non-labeled
thymidine, suggesting that nucleotide transporters are
involved in [11C]AZT uptake.
Discussion
In this study, we successfully determined whether it was
possible to measure the proliferative activity of tumors
in a tumor-bearing mouse model by PET scanning using
ab c
Fig. 5 Comparisons of the in vivo accumulation level of thymidine analogs in C6 tumor-bearing mice. Summed PET images (60 to 80 min) of C6
tumor-bearing mice after injection of 50 MBq of [11C]AZT, [11C]d4T or [11C]4DST (a). The color code for the standardized uptake value (SUV) is
shown at the bottom. Arrowheads indicate the C6 tumors. Arrows indicate bone or bone marrow regions. The graph in (b) shows the SUVs from
PET images for tumor tissue and bone. Data are presented as means ± S.D. (n = 4 to 6). One way ANOVA;**P < 0.01 vs. [11C]AZT and [11C]d4T
injected mouse. †P < 0.01 vs. [11C]d4T injected mouse. The graph in (c) shows the ratio of tumor-to-bone uptake of the labeled probes. One way
ANOVA;*P < 0.05 vs. [11C]4DST injected mouse. **P < 0.01 vs. [11C]d4T injected mouse
a b
Fig. 6 Metabolite analysis of injected [11C]AZT. a Representative TLC-radiochromatogram of plasma and tumor tissues at 30 min after i.v. injection
and of the bile at 60 min after i.v. injection of [11C]AZT. * indicates unmetabolized [11C]AZT. Arrowhead, arrow, and † indicate the metabolites a, b
and c, respectively. b The picture of TLC-chromatogram with unlabeled AZT metabolites visualized by ultraviolet (254 nm) irradiation
Tahara et al. EJNMMI Research  (2015) 5:45 Page 6 of 9
Fig. 7 Effect of thymidine on [11C]AZT uptake by C6 cells. [11C]AZT
(27 nM) uptake was measured after incubation of the cells at 37 °C
for 30 min in the presence or absence of thymidine (0.1 mM). Data
are averages of three independent experiments. Data are presented
as means ± SD
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The results revealed the usefulness of [11C]AZT for
in vivo tumor imaging.
In previous studies, tumor imaging of thymidine ana-
logs was used in order to assess their impact on cell pro-
liferation [5–11]. Recently, Toyohara et al. reported that
[11C]4DST was useful in imaging of tumor cell prolifera-
tion in vivo in mice and humans, because it was a sub-
strate of the enzyme involved in the phosphorylation of
thymidine but was resistant to degradation [5, 12, 13].
However, in those PET studies, [11C]4DST was also
highly accumulated in normal proliferative tissues such
as the bone marrow, spleen, and duodenum, which
made it difficult to distinguish tumors from normal pro-
liferative cells. In the present PET study of a mouse
tumor model, as shown in Fig. 5, although the maximal
SUV of [11C]AZT in tumor tissue was less than that of
[11C]4DST, the accumulation of [11C]AZT in tumor tis-
sue was much higher than that in the abovementioned
normal proliferative tissues. In addition, [11C]AZT
showed a higher tumor-to-bone marrow ratio than
[11C]4DST. The mechanism that underlies this difference
is unknown, but it may be related to the AZT substrate
specificity of enzymes in the thymidine-phosphorylation
pathway (thymidine kinase and thymidylate kinase), which
are described in a later paragraph. Based on these data,
[11C]AZT is expected to be useful for detecting tumors in
bone or bone metastasis. Further studies are needed tovalidate this possibility using bone metastasis model
animals.
Previous in vitro and in vivo studies have demon-
strated that AZT is metabolized to AZT-β-D-glucuro-
nide (AZT-G) by UDP-glucuronosyltransferase in
hepatocytes and that it is excreted mainly into the urine
in rats [20, 21], dogs [20], monkeys [20, 22], and humans
[20–22]. In the present TLC analysis, although very little
metabolism and degradation of [11C]AZT occurred
in vivo in mice, we did observe three hydrophilic metab-
olites of [11C]AZT, two of which were observed in the
bile (metabolite b and c, Fig. 6). Combined with the pre-
vious results [19–21], this finding suggests that the me-
tabolite b found in the bile may be AZT-G because its Rf
value showed the same position that of AZT-G (Fig. 6a,
b). AZT-G in bile was observed at 60 min after the injec-
tion but not at 30 min while much amount of metabolite
c was observed in bile and intestinal contents after
30 min at the lower position of AZT-G in TLC. There-
fore, it is possible to consider that low liver background
uptake may be derived by faster production of metabol-
ite c, which excreted into urine or intestinal contents via
the bile bladder and a little and delayed production of
AZT-G in liver. Since the metabolite c could not identify
in the present study, so it would need further study to
clarify the form.
Although AZT is known to be phosphorylated to
5′-monophosphate by enzymes in the thymidine-
phosphorylation pathway (thymidine kinase and thy-
midylate kinase), little AZT is converted to 5′-di- and
5′-tri-phosphate forms in humans [23], rats [24], and
mice [25]. Therefore, the one major metabolite (metab-
olite a) that was observed in tumor tissues (Fig. 6) may
be the 5′-monophosphate form of [11C]AZT (AZT-P).
In Fig. 6a and b, TLC analysis with unlabeled com-
pounds indicated that the Rf value of AZT-P closely re-
semble that of metabolite a. Furthermore, these data
suggest that [11C]AZT was converted to AZT-P after
uptake in tumor cells but not in the blood.
Nucleoside transporters are involved in the cellular
uptake of nucleoside analog antiviral drugs, as well as of
nucleosides. In the present study, the addition of thymi-
dine completely blocked the cellular uptake of [11C]AZT
by C6 tumor cells, strongly indicating the specific involve-
ment of nucleoside transporters (Fig. 7). In previous stud-
ies, several other transporters, including Na+-dependent
concentrative nucleoside transporters (CNTs: human (h)
/rat (r) CNT1 and hCNT3) [26, 27], Na+-independent
equilibrative nucleoside transporters (ENTs), h/rENT2
[24], organic anion transporters (OATs) (h/rOAT1-3 and
hOAT4) [28–32], and the organic cation transporter
rOCT1 [33], were reported to be involved in AZT cellular
uptake. Although the profile of nucleoside transporters in
tumors has not yet been confirmed, these transporters
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[11C]AZT uptake. Further studies are needed to identify
the transporter(s) involved in [11C]AZT uptake.
Some studies have attempted to visualize the localization
of viruses, such as HIV, within the cell using fluorescent
proteins or fluorochromes in order to reveal the processes
of cell invasion and virus particle maturation [34, 35]. It is
well known that NRTIs such as AZT and d4T suppress the
replication of HIV by inhibiting the activity of its reverse
transcriptase [1, 2], indicating that [11C]AZT or [11C]d4T
could have a role as a PET probe for imaging virus
localization and virus dynamics in vivo. Further studies in-
volving PET experiments and virus-infected animals are
necessary to clarify virus localization and dynamics in vivo.
Conclusions
We have assessed whether the proliferative activity of
tumor cells can be visualized by PET analysis using
[11C]AZT or [11C]d4T, and have demonstrated that
[11C]AZT, but not [11C]d4T, is highly accumulated in
proliferating tumor tissues compared to normal prolifer-
ating tissues. [11C]AZT might therefore be a useful PET
probe for tumor imaging.
Additional file
Additional file 1: Figure S1. PET images of C6 and HeLa tumor-
bearing mice between 30 and 60 min after injection of 50 MBq of
[11C]AZT (A) and [11C]d4T (B). Arrows and arrowheads indicate the C6
and HeLa tumors, respectively. Figure S2 [11C]AZT and [18F]FDG uptake
in aseptic inflammation model mice. Representative coronal PET images
for [11C]AZT (A) and [18F]FDG (B) between 60–80 min after injection.
Yellow dot circles indicated turpentine oil-induced inflammatory tissue.
Biodistribution of [11C]AZT (C) and [18F]FDG (D) in turpentine oil-treated
(black bar) and untreated (white bar) posterior thigh muscles. Data are
means ± SD (n = 5, ***P < 0.001). Histological analysis by hematoxylin
and eosin staining of turpentine oil-untreated (E) and treated (F) muscles.
Scale bar = 1 mm. Figure S3 The accumulation levels in bone and tumor of
[11C]d4T, [11C]AZT, and [11C]4DST. Thigh bones and tumors were collected
after 80 min PET probe injection. Radioactivities in these tissues were
measured by γ-well counter. The graph in (A) shows the %ID/g for
tumor tissue and bone. Data are presented as means ± SD (n = 4 to 6). **P
< 0.01 vs. [11C]AZT and [11C]d4T injected mouse. †P < 0.01 vs. [11C]d4T
injected mouse. The graph in (C) shows the ratio of tumor-to-bone uptake
of the labeled probes. *P < 0.05 vs. [11C]4DST injected mice. **P < 0.01 vs.
[11C]d4T injected mice.
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